NEO
Neogenomics Inc
$
11.480
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
11.520
Open
10.600
VWAP
11.26
Vol
2.61M
Mkt Cap
1.49B
Low
10.360
Amount
29.41M
EV/EBITDA(TTM)
3.56K
Total Shares
127.71M
EV
1.66B
EV/OCF(TTM)
121.48
P/S(TTM)
2.07
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
198.82M
+9.65%
0.042
+5.77%
187.98M
+11.87%
0.024
-52.3%
Estimates Revision
The market is revising Upward the revenue expectations for NeoGenomics, Inc. (NEO) for FY2025, with the revenue forecasts being adjusted by 0.39% over the past three months. During the same period, the stock price has changed by 73.81%.
Revenue Estimates for FY2025
Revise Upward
+0.39%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.06%
In Past 3 Month
Stock Price
Go Up
+73.81%
In Past 3 Month
11 Analyst Rating
15.77% Upside
Wall Street analysts forecast NEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEO is 13.29 USD with a low forecast of 11.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
6 Hold
0 Sell
Moderate Buy
15.77% Upside
Current: 11.480
Low
11.00
Averages
13.29
High
17.00
15.77% Upside
Current: 11.480
Low
11.00
Averages
13.29
High
17.00
Piper Sandler
Overweight
maintain
$11 -> $12
2025-11-10
Reason
Piper Sandler
Price Target
$11 -> $12
2025-11-10
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on NeoGenomics to $12 from $11 following quarterly results. The firm keeps an Overweight rating on the shares.
BofA
Neutral
maintain
$11
2025-10-29
Reason
BofA
Price Target
$11
2025-10-29
maintain
Neutral
Reason
BofA raised the firm's price target on NeoGenomics to $11 from $6.50 and keeps a Neutral rating on the shares after "a solid quarter." The firm views the quarterly update as "constructive," but sees questions on the sustainability of the growth rate and the competitive position, the analyst tells investors.
Leerink
Market Perform
maintain
$12 -> $14
2025-10-28
Reason
Leerink
Price Target
$12 -> $14
2025-10-28
maintain
Market Perform
Reason
Leerink raised the firm's price target on NeoGenomics to $14 from $12 and keeps a Market Perform rating on the shares. The company reported a Q3 beat and is taking investor feedback by proving "beatable guidance and realistic targets," the analyst tells investors in a research note.
TD Cowen
Buy
upgrade
$10 -> $12
2025-09-12
Reason
TD Cowen
Price Target
$10 -> $12
2025-09-12
upgrade
Buy
Reason
TD Cowen raised the firm's price target on NeoGenomics to $12 from $10 and keeps a Buy rating on the shares after hosting meetings with management. The firm left more constructive on NeoGenomics's new product launches, saying MolDX reimbursement remains the "final gate" for a 2026 ramp.
Stephens
Overweight
maintain
$11
2025-09-02
Reason
Stephens
Price Target
$11
2025-09-02
maintain
Overweight
Reason
Stephens raised the firm's price target on NeoGenomics (NEO) to $11 from $6.50 and keeps an Overweight rating on the shares after the company announced that a North Carolina district court ruled in the company's favor in the litigation with Natera (NTRA). The ruling grants NeoGenomics the ability to broadly commercialize RaDaR ST and removes an overhang, says the analyst, who believes the decision strengthens NeoGenomics' positioning in oncology and helps to support more durable growth.
Piper Sandler
Overweight
downgrade
$12 -> $11
2025-08-04
Reason
Piper Sandler
Price Target
$12 -> $11
2025-08-04
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on NeoGenomics to $11 from $12 following quarterly results. The firm keeps an Overweight rating on the shares.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Neogenomics Inc (NEO.O) is 74.55, compared to its 5-year average forward P/E of 1.42. For a more detailed relative valuation and DCF analysis to assess Neogenomics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
1.42
Current PE
74.55
Overvalued PE
129.00
Undervalued PE
-126.16
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
121.99
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1437.26
Undervalued EV/EBITDA
-1193.29
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
4.50
Current PS
0.00
Overvalued PS
7.97
Undervalued PS
1.03
Financials
Annual
Quarterly
FY2025Q3
YoY :
+11.90%
187.80M
Total Revenue
FY2025Q3
YoY :
+5.80%
-14.18M
Operating Profit
FY2025Q3
YoY :
+53.28%
-27.13M
Net Income after Tax
FY2025Q3
YoY :
+50.00%
-0.21
EPS - Diluted
FY2025Q3
YoY :
-136.70%
570.00K
Free Cash Flow
FY2025Q3
YoY :
-3.99%
42.84
Gross Profit Margin - %
FY2025Q3
YoY :
-28.14%
-2.40
FCF Margin - %
FY2025Q3
YoY :
+36.97%
-14.45
Net Margin - %
FY2025Q3
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
2
212.3K
USD
Months
6-9
7
536.4K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
3
672.9K
Volume
Months
0-12
3
419.6K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
16.0K
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
2
212.3K
USD
Months
6-9
7
536.4K
USD
Months
0-12
0
0.0
USD
Months
NEO News & Events
Events Timeline
2025-10-30 (ET)
2025-10-30
12:54:00
NeoGenomics to Showcase RaDaR ST Bridging Study at ISLB 2025
2025-10-28 (ET)
2025-10-28
07:39:33
NeoGenomics Supports FY25 Revenue Forecast of $720M-$726M, Aligning with Consensus of $722.46M
2025-10-28
07:36:59
NeoGenomics announces Q3 adjusted EPS of 3 cents, surpassing consensus estimate of 2 cents.
Sign Up For More Events
Sign Up For More Events
News
4.5
11-16WSJNew Rare-Earths Facility in Europe Highlights Challenges in Reducing Dependence on China
5.0
10-30NewsfilterNeoGenomics to Showcase RaDaR ST Bridging Study at ISLB 2025, Highlighting Consistent MRD Detection in Solid Tumors
9.5
10-28NASDAQ.COMTranscript of NeoGenomics (NEO) Earnings Call for Q3 2025
Sign Up For More News
People Also Watch
TSLA
Tesla Inc
391.090
USD
-1.05%
GOOGL
Alphabet Inc
299.660
USD
+3.53%
AVGO
Broadcom Inc
340.200
USD
-1.91%
AMZN
Amazon.com Inc
220.690
USD
+1.63%
META
Meta Platforms Inc
594.250
USD
+0.87%
MSFT
Microsoft Corp
472.120
USD
-1.32%
AAPL
Apple Inc
271.490
USD
+1.97%
WMT
Walmart Inc
105.320
USD
-1.67%
GOOG
Alphabet Inc
299.650
USD
+3.33%
NVDA
NVIDIA Corp
178.880
USD
-0.97%
FAQ
What is Neogenomics Inc (NEO) stock price today?
The current price of NEO is 11.48 USD — it has increased 8.3 % in the last trading day.
What is Neogenomics Inc (NEO)'s business?
What is the price predicton of NEO Stock?
What is Neogenomics Inc (NEO)'s revenue for the last quarter?
What is Neogenomics Inc (NEO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Neogenomics Inc (NEO)'s fundamentals?
How many employees does Neogenomics Inc (NEO). have?